Research · 2026-04-17
By Alice Kay · Last reviewed 15 Oct 2026
Retatrutide research status for labs
Research-use notice: This article summarizes published scientific literature for educational purposes. It is not medical advice and does not provide dosing, administration or human-use information. Findings described in the literature do not apply to any BlueNex Labs product, which is supplied only for in-vitro laboratory research and not for human or animal use.
Direct answer
See where public records place investigational retatrutide and the TRIUMPH program. Read the laboratory status note, then the trial recap.
Scope
Metabolic & energy-signaling models. Incretin, mitochondrial, and secretagogue literature. These notes summarize published models — they are not catalog pages.
This note does not claim that Alice Kay authored any cited paper.
Retatrutide (LY3437943) is an investigational triple agonist at GLP-1, GIP, and glucagon receptors, developed by Eli Lilly. As of the status check for this article, it is not FDA-approved and is not a Health Canada-authorized medicine. This page tracks public regulatory status. It is not the shop listing.
What “investigational” means
Public sources describe an IND-stage program and Phase 3 work under the TRIUMPH name. An advisory article or blog that calls retatrutide “approved” is incorrect until a regulator issues that decision. An NDA timeline in secondary media is a forecast, not a catalogue fact.
What trials are designed to measure
Registered studies evaluate metabolic endpoints such as glycemic markers and body-weight change in defined cohorts, plus safety. Reporting a trial endpoint is not the same as advertising a consumer outcome. Published phase 2 papers are cited on retatrutide clinical trial notes. This page does not repeat uncited sponsor readout figures.
Laboratory lots
The 10 mg, 20 mg, and 30 mg research fills are separate listings: retatrutide 10 mg, retatrutide 20 mg, and retatrutide 30 mg. Certificate rows are 10 mg, 20 mg, and 30 mg. Those pages are for laboratory purchasing. They are not Lilly trial drug and they are not a prescription product.
Catalogue cross-reference
A research vial on this catalogue is not the investigational trial supply. Confirm lot identity on the COA before an assay, and do not treat secondary media timelines as a purchasing specification.
Orders ship inside Canada only after Interac e-Transfer checkout. Sold-out SKUs remain listed and cannot be added to the cart. Match each vial to its own Certificate of Analysis when a lot is published. Research use only. Not for human or veterinary use.
Sources for these claims
Phase 2 descriptions of retatrutide as a GIP, GLP-1, and glucagon receptor agonist are Jastreboff and colleagues, New England Journal of Medicine, 2023 (PMID 37366315, NCT04881760) and Rosenstock and colleagues, The Lancet, 2023 (PMID 37385280). Those papers describe the sponsor program. They are not a specification for a lyophilized research solid. FDA approval status is checked against Drugs@FDA. The July 2026 Pharmacy Compounding Advisory Committee meeting is a separate record: FDA advisory calendar. Canadian authorization is checked against the Health Canada Drug Product Database.
References
This note does not add a separate citation list. Named papers, when the body links them, stay in the text above.
Research use only. BlueNex Labs does not provide medical or veterinary advice. Confirm your institution’s policies before purchase. Lot-file rules for this note are on the documentation standards page. By Alice Kay.